Connecticut Oncology Association

Specialty Drug Carve-out Programs and What They Mean to Practices and Patients - Dawn Holcombe MBA FACMPE ACHE

  • 26 Jan 2023
  • 6:00 PM - 8:30 PM
  • Sheraton Hartford South, 100 Capital Blvd, Rocky Hill, CT


  • Charter Oak Corporate Members may reguster up to two attendees for free - Others must register as Corporate Event Paid Members or Guests
  • Corporate Nutmeg Members are allowed 1 free attendee, other attendees after that should register as Corporate Event Paid Member or Guest
  • For certain webinars, there will be no charge for additional corporate registrations, subject to capacity limitations

Registration is closed

Greetings,  Please join us for the CT Oncology Association on Thursday, Jan. 26, 2023 in person 


Meeting Date: Thursday January 26, 2023     Time: Evening Meeting 6 p.m. to 8:30 p.m.

Location: Sheraton Hartford South (formerly Rocky Hill Marriott) Rocky Hill

6 pm registration, 6:20 buffet dinner, 6:40 meeting starts

Topic  “Specialty Drug Carve-out Programs and what they Mean to Practices and Patients”

The specialty drug carve-out issue is rapidly emerging as one of the hottest discussions of the year.  These vendors are deceiving their employer customers, confusing and harming patients and disrupting the patients access to care, as well as draining the resources of free drug programs and patient support programs.   They basically declare that expensive prescribed drugs to treat rare and orphan diseases, and cancer are not essential health benefits protected under the ADA and therefore fair game for predatory cost sharing, illegal importation of cheaper drugs, and draining of free drug and foundation programs established for truly needy patients.  The impact on patients and the treating providers can be significant from these programs, but they are difficult to identify and track.  Awareness will be the precursor to reacting and addressing these dangerous programs. 

Dawn Holcombe MBA FACMPE ACHE, President of DGH Consulting, has experience in payer trends and relations, practice strategy and operations, USP Chapter 797 and 800 compliance, especially in the field of oncology.  Dawn Holcombe’s thirty years in healthcare have included executive, strategic, financial, and marketing positions in academic and private health systems as well as physician practices.

She is the Editor-in-Chief of the national Oncology Practice Management journal, a past President of the national Administrators in Oncology Hematology Assembly (AOHA) of the Medical Group Management Association (MGMA) and is a Fellow in the American College of Medical Practice Executives (ACMPE), earning her MBA at the University of Michigan.  She also serves as the President of the National Oncology State Network (NOSN), the Executive Director of the Connecticut Oncology Association, and the Director of the Oncology Institute for the NAMCP Medical Directors.  

This is a not to be missed program for physicians and staff in every group in CT (hospital based or private.)  Feel free to invite your local patient support, foundation, and advocacy representatives, since identifying and dealing with these programs affect them as well.  Pharmaceutical companies with patient support and free drug programs are seeing their resources for need patients depleted by the growth of these specialty drug carveout programs (also known as alternate funding models.)

Top highlights and takeaways to be included are:

  • ·         Understanding the Attraction of these Programs for Self-Insured Employers and their Employees
  • ·         Learn the players and the details of the programs, their pitches and the fine print details that can hurt patients
  • ·         Review the Adverse Consequences: Real and Potential
  • ·         Develop a CT Strategy for Tracking and Responding

Bring your physician colleagues and staff.  You may register on the CT Oncology Association website,, or by email to

We will also be discussing plans for the Connecticut Oncology Association projects and meetings in 2023, and look forward to participation from practice physicians, administration and nurses.  All are encouraged to attend.  We also extend a warm welcome to any Residents or Fellows who wish to join us.

Please join the Connecticut Oncology Association in thanking our 2022 Charter Oak Partners to Date for helping us to bring this education program to our members: Abbvie, Bristol Myers Squibb, Genentech, Johnson & Johnson, Merck, Regeneron, Sanofi Genzyme, Seattle Genetics and Takeda Millenium.  2023 Corporate Partnership Applications are Now Available

We would also like to thank our other 2022 Nutmeg level corporate partners: Aveo, Astellas, Eisai, Incyte, Natera, Novartis, Pfizer and Taiho Oncology.  We look forward to welcoming these partners and others in 2023.

Please Complete & email the Registration Information Below by Monday January 23 at noon. Earlier registration would be appreciated for food counts.

I will be attending the CtOA Meeting, Thursday Jan. 26, 2023 at the Sheraton Hartford South Yes____ No___

Please register at,  Or email

It is important to provide contact phone and email information, in case of adverse weather or unexpected issues.

Connecticut Oncology Association (CtOA)

c/o Dawn Holcombe

33 Woodmar Circle
South Windsor, CT  06074
(860) 305-4510

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Powered by Wild Apricot Membership Software